Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5643_Библиотеки_им_академика_М_И_Перельмана.pdf
154 Herbal Pharmacopeia
enable the researchers to trace new bioactive molecules of pharmaceutical importance and foster
more development on the use of herbal medicine as drugs.
7.4.1 MetaboloMics aPProacHes in Herbal Drug Discovery
The study of small molecules, which includes drug metabolites, is a comparatively recent branch
of science which entails the characterization of small molecules with the help of various physical
methods including nuclear magnetic resonance (NMR), mass spectrometry, along with chromatography [83]. It also allows a special type of ‘top- down’ examination of other complex biological
structures, such as cells [84]. The exibility and the broad spectrum of the analysis methods, which
comprise mass spectrometry [85–90], NMR spectroscopy [91–96], and infrared spectrophotometry
[97], integrated in the metabolomics has boosted the eld’s growth. With the help of the available instruments, thousands of metabolites in complex biological samples might be evaluated [98].
There is no one analytical tool or technique that can be used to detect every single metabolite in
a biological model because of the complexity of the biological system and the many substances
in the metabolome. These more recent techniques are being combined to increase the diagnostic
effectiveness and dereplication procedures, hence broadening the range of metabolites that are being
identied. The primary analytical methods that have been often used to produce metabolomics data
are MS and NMR. However, for the purposes of metabolite separation, identication, and quantication, various analytical hyphenated platforms—such as gas chromate- MS (GC- MS), HPLC,
UPLC, and compound systems of those mentioned—are being employed more appropriately [99].
Although NMR may yield precise and reliable results quickly, making it suitable for examining bulk
materials, mass spectrometry's great sensitivity makes it possible to analyze many metabolites both
qualitatively and quantitatively.
7.4.2 genoMic aPProacHes
‘Genome mining’ is the potential function and chemical connections between bioactive natural
compounds and the bioinformatics inquiry that identies the biosynthesis route of those compounds
[100]. More precisely, genome mining involves discovering earlier unidentied gene clusters
responsible for the biosynthesis of natural products within the genomes of sequenced organisms.
This process includes examining the enzymes encoding these gene clusters by sequencing, and
experimentally identifying the result of the resulting products (Figure 7.2) [101].
The majority of clinically authorized medications, including antibiotics, are derived from natural
materials. Combinatorial biosynthesis approaches is the novel technique for the identication of
naturally occurring compounds with biotechnological uses, having been made possible by the development of new bioinformatics, genetics, and analytical tools [102, 103]. These methods have demonstrated the capability of organisms, especially microorganisms generating bioactive natural
compounds, has been undervalued, in conjunction with bioinformatic methodologies [104]. The
genomes of these creatures have been sequenced, and genome mining techniques have been used to
further investigate them [105]. Biosynthetic gene clusters that have an unknown origin are referred
to as orphan and cryptic and may be involved in the production of additional secondary metabolites.
Their origins have been revealed by genome analysis [104]. Genome mining uses various bioinformatic procedures to nd gene that code for novel natural compounds of biological benets [106].
The growing prevalence of serious diseases (like cancer) and the declining effectiveness of current
medications have made it imperative to nd novel therapeutic entities, which is why genome mining
is so important [107]. Additionally, by encouraging cost- cutting and their commercial application,
the components contained in the biosynthetic gene clusters help enhance the production of both
natural and engineered products [105].
Biotechnological Approaches for Herbal Drug Discovery 155
FIGURE 7.2 Genomic approach for the discovery of drugs.
7.5 CASE STUDIES TREATED WITH BIOTECHNOLOGICALLY- EXTRACTED
HERBAL DRUGS
Many of the diseases that have previously been treated with pharmacological drugs are today treated
with herbal extracts. The herbal compounds are readily available and have either no or very rare
side effects. Here are some of the case studies now treated with biotechnologically extracted herbal
sources.
7.5.1 Quinine for Malarial treatMent
Malaria, a very fatal disease caused by the Plasmodium parasite, has plagued humankind for generations. The bark of the cinchona tree (Cinchona ofcinalis) is widely used by Native tribes of South
America as a fever treatment [108]. Back in the 17th century, quinine, a bioactive substance present
in cinchona bark, was discovered to be a very effective treatment for malaria [109]. This discovery
marked a major breakthrough in the treatment of the illness; quinine remained a vital anti- malarial
drug for decades until more modern treatments were developed [110].
The signicance of plant- based medicine identifying the healing potential of the natural environment is the persistent understanding of ancient civilization [111]. These early methods contributed
to the advancement of healthcare by laying the foundation for the development of modern pharmacology [112]. In addition, they stress the need to protect and honor our natural resources while also
looking into the potential medical benets of natural products based on plants in the contemporary
eld of pharmaceutical study and development.
156 Herbal Pharmacopeia
7.5.2 asPirin for Pain anD tHe treatMent of inflaMMation
The development of modern pharmacology has been greatly inuenced by the historical usage of
herbal treatments. One important example of this phenomena is aspirin, which is a common analgesic used globally. The willow tree, which is the commonly known specie of the Salix alba species,
is the original source of aspirin, which was initially isolated from its bark. This natural therapy was
transformed into a synthetic version through a synthesis procedure. Consequently, it has gained
widespread recognition and is employed globally as an essential element in pain management. As a
result, the variety of medicinal compounds found in nature has had a big impact on the present- day
pharmaceutical business. One example of this is the transition from traditional herbal remedies to
synthetically manufactured pharmaceutical molecules, which is what happened with aspirin [113].
Willow bark was utilized as an analgesic by ancient civilizations such as the Greeks and Egyptians.
The successful extraction of the active component, acetylsalicylic acid, throughout the 19th century
led to a dramatic change in the management of pain and inammation [114].
7.6 LIMITATIONS IN HERBAL DRUG DISCOVERY
Herbal drug discovery faces several limitations, including regulatory hurdles and challenges associated with emerging technologies.
7.6.1 regulatory HurDles
Regulatory frameworks for herbal medicines vary globally, with disparities in policies and enforcement mechanisms affecting the herbal products in terms of the quality, safety, and efcacy of herbal
products. In many countries, such as those in sub- Saharan Africa, national regulations regarding the
use of herbal medicines remain scarce; this makes it possible for counterfeit herbal remedies to ood
the market and therefore is a potentially grave source of danger to the health of its consumers. This
is due to the fact that there appears to be no recognized protocol at both national and international
levels for the formulation of policies and the implementation of quality control on herbal drugs
[115]. Conrmation of in vitro bioassay techniques is important in the investigation of most oriental
medicinal compounds. It is , however, faced with several difculties as to the accuracy of subsequent
ndings. Any validation of the bioassay method is crucial for the identication of the pharmacological activity of the compounds derived from a herb. Nevertheless, variability in the validation procedures can lead to variations in efcacies’ estimates. Such an absence of the uniform validation
process is one of the factors to complicate the process of identifying adequate experimental models
for discovering herbal drugs, not to mention translating in vitro data into clinical reality [116].
Another crucial factor of herbal product commercialization and safe use is the lack of standard policies and quality control. The spiking of herbal drugs with synthetic substances increases the danger
to consumers and demonstrates the need for quality control measures. However, there are technical
difculties in identifying and controlling some of these impurities in the nal herbal products with
regards to quality and safety. Thus, there is a need to establish efcient analytical methods and product regulation [117]. The major problem of notably various multiple- herb formulae is in pointing to
which of the numerous compounds have therapeutically active components. Many herbal medicines
are reported to consist of several bioactive compounds so there is a problem of analysing the individual constituents for pharmacodynamics studies. Lack of standardized validation protocols results
in the limitation of this whole process up to in vitro tests and the herbal compounds cannot be clinically practiced [118]. Market factors that ank the production and sale of herbal supplements include
statutes and rules by federal agencies such as the US FDA, which inhibit the marketing of substandard supplements. The current regulation of herbal products relies on the extent to which the authorities may choose to enforce standards with regard to the products’ quality and performance. Their
failure to prescribe improved instrumentalities of regulation, also making it difcult to assure safety
Biotechnological Approaches for Herbal Drug Discovery 157
and the sound prole of herbal drugs in the market [119]. Regulatory problems in developing countries, as well as worldwide issues regarding the quality of herbal medicine and compliance to good
standards, are among the issues that slow down the development of the herbal business. The policies
of the FDA and other related bodies have introduced measures that limit market access for substandard and adulterated herbal products, thereby calling for good and established policies that will
protect society. As a result of diverse regional policies that are not in harmony, there is a major challenge in the formulation of the herbal drugs and selling them around the world [14]. Hence with
regard to herbal wound care products, regulatory and legal hurdles are the key barriers to the creation and commercialization of safe and efcacious remedies. Due to the factors such as product
registration, product quality standards, and requirements needed to meet the regulatory agencies’
standards present some hurdles regarding the entry of herbal wound care products into the market.
There are issues with the regulation behavior that slow down the process of commercialization of
herbal therapies, and its usage in healthcare systems [120]. The use of chemicals and other substances not approved by doctors and other medical practitioners on patients remains extremely rampant in regions such as Nigeria explains the difculties involved in regulating the usage of herbal
products. The easy access to these herbal remedies from sources other than the formal pharmacies
and the absence of measures being taken to ensure that the herbs meet the specied quality catches
a lot of blame as far as consumption of the herbal medicines are concerned. Lack of and/or insufcient regulation of traditional herbal remedies for sale thus contributes to public health issues and
implies the necessity of the improved regulation of these types of medications [121]. Challenges of
pharmaceutical companies get into the development of orphan drugs mainly because the patient
pool for these diseases is limited which brings the issue of nance into play. The speciality market
of rare disease therapies eliminates the prot- making potential of mainstream research approaches
and hinders the funding of further exploration on herbal drugs for rare diseases. Regulatory issues
inuence herbal medicines' accessibility and acceptance in medical settings and hinder their timely
and efcient commercialization [122]. Among the challenges that are encountered during the development of herbal compounds to treat inammatory bowel disease (IBD) include: Regulatory frameworks limiting the use of safety and efcacies of the herbal medicine. Another limitation is the
requirement to conform to strict preclinical and clinical testing procedures that are entailed by compliance with regulatory measures, which increases the drug development process’s complexity and
timeframe. The stringent regulation regarding the formulation of herbal drugs complicates safety
and efcacy concerns, which hamper research in the development of new treatments for IBD [123].
Nonetheless, medicinal plants represent promising reservoirs of novel therapeutic leads in the process of drug discovery. Current issues include the difculties in identifying appropriate highthroughput screening bioassays and how to increase the production of bioactive molecules for
translational purposes. The number of screening assays has not stabilized which signicantly hinders the recognition of molecules contained in herbs that can be therapeutic. Furthermore, difculties in the procurement and increasing the production of plant- derived bioactive molecules limit the
conversion of folk medicines into drugs [124]. While attempting to establish ways of excluding
herbal ingredients that hit specic types of pathways, it is a challenge to do so because herbs are not
as straightforward as one- targeted or one- pathway affected compounds. Herbal ingredients work
through the combined action of multiple fractions and inuences different bio- pathways. This is
why the straightforward drug target hunting technology does not work well in this context. Due to
the diverse composition of herbal preparations, different strategies are used to discover and validate
the molecules possessing required pharmacological effects [15]. Imbalances in the global accessibility of drugs concerns the opportunities to use therapeutic monoclonal antibodies and their availability in pediatric populations. The shortage of treatment antibodies restricts the healthcare available to
children with different diseases, thereby making a statement about healthcare inequalities. These
problems around accessing therapeutic monoclonal antibodies speak of the need to have policies
that will allow the availability of vital medications in the market [125]. Evaluating the adverse
drug reactions (ADRs) linked with herbal medicines suggests issues in the legal standing, risk
158 Herbal Pharmacopeia
assessment, and quality standards of herbs and supplements. The low awareness among the healthcare workers regarding herbal products, together with poor efcacy, an absence of regulatory and the
lack of quality control measures are just some of the factors which are attributed to the hazards
related to the usage of herbal medicines. To tackle these challenges, more stringent regulatory measures at the administrative level and safety control of the herbal compounds are mandatory in order
to protect the health of the community [126].
7.6.2 eMerging tecHnologies
Although innovative technologies have the potential to radically enhance drug discovery, their application in the study of herbal medicine is still limited by a number of difculties. The incorporation of
Computer- Aided Design and Drafting (CADD) and other related tools in the development of herbal
drugs entails aspects of overcoming technical difculties in adopting these novel technologies in
coping with the complications that surround the structures of most natural products. The weaknesses
that have been observed during the application of these advanced technologies on herbal drug discovery therefore call for an invention of strategies that will favor the discovery of natural products
[127]. These confusing single botanical drugs could be due to the multifaceted medical applications
of single botanical drugs that Ayurveda and other traditional medical practices have helped in using,
thereby messing up the concept of precise herbal medicinal usage. The literature review followed
this topical approach because the medicinal plants are generally complex biological products used
in the treatment of diverse conditions whose pharmacology cannot easily be standardized. These
ndings around herbal medicine usage show that there was a dire need for intensive and exhaustive
research coupled with positive indicators to support the healing prowess of those products [128].
Metabolomics based on mass spectrometry is, and will become, one of the most efcient techniques
for the analysis of metabolic proles, targets, and the effectiveness of herbal medicine. It has been
found that metabolomics in herbal drug discovery helps the researchers to analyse the metabolites
of the herb and the working of the drug [129]. Integrated use of the metabolomics in diagnosing
and assessing the impact of herbal remedies improves the methods’ accuracy and efciency, most
notably in terms of evaluating the metabolic changes induced by natural substances [129]. The process of collection, identication, and cataloging of reference DNA barcodes for goal identication
of recipes and herbs reveals the signicance of quality measures for protecting the conventional and
modern herbal medicines’ industrial markets [130]. Implementation of the genetic body reference
standards for plant products in herbal products helps to prevent the sale of counterfeit products and
to meet the requirement of the regulatory agencies. The utilization of DNA barcoding technologies
solves some of the issues related to the identication of the botanical source for herbal products and
eliminates the aspects of addition and misidentication of the plant species. Information regarding
the efcacy and therapeutic achievements of complex herbal formulas in the context of herbal medication combinations can be acquired with the use of knowledge graph- based methodologies. The
use of knowledge graphs in the research of herbal medicines helps in the determination of combined
effects and the role of multiple compounds present in a drug formulation. This approach is vital in
overcoming issues related to the safety and effectiveness of herbal formulations in relation to their
combination form, which is useful in generating important information concerning improvement in
the treatment regimen of the patients [131]. The relevance of toxicity and standardization concerns
in herbal treatment during the COVID- 19 pandemic highlight some of the problems that are encased
by the regulation of the use of herbs. Possible issues of quality control, interaction of herbal and
drug and, generally, the absence of adequate regulatory policies add challenges to the processes of
safety and efcacy of herbal items in public health emergencies. These regulatory barriers show that
there is a gap in monitoring herbal therapies with subsequent need of quality assurance of the drugs,
and standardized methods of using herbal medicines [132]. A regulator has a signicant duty to
ensure the quality and safety of herbal medicines, but there are difculties in the effective management of herbal products. Thus, the development of new forms of healthcare calls for the elaboration
Biotechnological Approaches for Herbal Drug Discovery 159
of more detailed regulatory measures that contain references to the specics of herbal preparations. Balancing the need for regulatory oversight with the promotion of herbal medicine innovation requires collaborative efforts between regulatory agencies and industry stakeholders [133].
Difculties in ensuring the safety of herbal medicines underscore the importance of robust pharmacovigilance systems and the measurement of quality control. The lack of standardized protocols for
assessing the efcacy and safety of herbal products hinders the identication of potential risks and
adverse reactions. Enhancing pharmacovigilance practices and regulatory oversight is essential for
conrming the responsible use of herbal drugs and safeguarding public health [134].
REFERENCES
1. Rivera, J. O., Loya, A. M., & Ceballos, R. (2013). Use of herbal medicines and implications for conven-
tional drug therapy medical sciences. Altern. Integ. Med., 2(6), 1–6.
2. Mishra, P., Kumar, A., Nagireddy, A., Mani, D.N., Shukla, A.K., Tiwari, R., et al. DNA barcoding: An
efcient tool to overcome authentication challenges in the herbal market. Plant Biotechnol. J. 2016 Jan
1;14(1):8–21.
3. Gurib- Fakim, A.. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol. Asp. Med.,
2006;27(1):1–93.
4. Rout, J., Sajem, A.L., & Nath, M. Medicinal plants of North Cachar Hills district of Assam used by the
Dimasa tribe. Indian J. Tradit. Knowl. 2012 [cited 2024 Jul 20];11(3):520–7. Available from: https://
nopr. niscpr. res. in/ handle/ 123456789/ 14395
5. Ekor, M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in
monitoring safety. Front. Neurol. 2014;4 Jan:177.
6. Hussin, A. H.. Adverse effects of herbs and drug- herbal interactions. Malays. J. Pharm. Sci.
2002;1(2):39–44.
7. Lahlou, M. The success of natural products in drug discovery. 2013 [cited 2024 Jul 20]; Available from:
https:// www. scirp. org/ html/ 3- 2500287_33502.htm
8. Fabricant, D.S., & Farnsworth, N.R. The value of plants used in traditional medicine for drug discovery.
Environ. Health Perspect.. 2001 [cited 2024 Jul 20];109(Suppl. 1):69–75. Available from: http://ehpnet1.
niehs.nih.gov/docs/2001/suppl- 1/69-75fabricant/abstract.html
9. Christenhusz, M., & Phytotaxa, J.B.. The number of known plants species in the world and its annual
increase. Phytotaxa. 2016 [cited 2024 Jul 20];261(3):201–17. Available from: https://phytotaxa.mapress.
com/pt/article/view/16325
10. Parasuraman, S. Herbal drug discovery: challenges and perspectives. Curr. Pharmacogenomics Pers.
Med. 2018;16(1):63–68.
11. Noviana, E., Indrayanto, G., & Rohman, A. Advances in ngerprint analysis for standardization and qual-
ity control of herbal medicines. Front. Pharmacol. 2022 Jun 2;13:853023.
12. Roy, D., Chakraborty, A., Mukherjee, P., Ghosh, B., & Chakraborty, M. Recent advances in herbal medi-
cines – An updated review. Asian J. Pharm. Res. Dev. 2022 Feb 15;10(1):45–8.
13. Batiha, G. E. S., Beshbishy, A. M., El- Mleeh, A., Abdel- Daim, M. M., & Devkota, H. P.. Traditional uses,
bioactive chemical constituents, and pharmacological and toxicological activities of Glycyrrhiza glabra
L. (Fabaceae). Biomolecules 2020;10(3):352.
14. Hossain, C. M., Gera, M. E. E. T. A., & Ali, K. A.. Current status and challenges of herbal drug develop-
ment and regulatory aspect: a global perspective. Asian J. Pharm. Clin. Res. 2022;15:31–41.
15. Tian, S., Li, Y., Xu, J., Zhang, L., Zhang, J., Lu, J., … & Zhang, W.. COIMMR: a computational frame-
work to reveal the contribution of herbal ingredients against human cancer via immune microenvironment and metabolic reprogramming. Brief. Bioinform. 2023;24(6): bbad346.
16. Atoe, K., Idu, M., Ikhajiagbe, B., & Bakre, A. G.. The Inuence of Methanol Extracts of Some Plant
Species Used in the Management of Pregnancy- Related Symptoms on the Reproductive Parameters of
Pregnant Wistar Rats. Trop. J. Nat. Prod. Res. 2023;7(12):5658–5663.
17. Darji, S., Rani, K.S., & Patani, P. A Review on Herbal Nanoparticles. J. Pharm. Negat. Results. 2022 Nov
7;1990–2002.
18. Li, X.Z., & Zhang, S.N. Recent advance in treatment of osteoarthritis by bioactive components from
herbal medicine. Chin. Med.. 2020 Aug 1;15(1).
160 Herbal Pharmacopeia
19. Manmuan, S., Manmuan, P., Yoykaew, P., Thuetong P., Asipong, P., Riantong, N., et al. Evaluation of
standardized extract of centella asiatica on cell viability and repressive cancer migration in metastatic
colorectal cancer cells in vitro. Walailak J. Sci. Technol. 2021;18(5):1–18.
20. Thomford, N.E., Yahaya, E.S., Ekor, M., & Awortwe, C. Turning up the Volume for Precision Herbal
Medicine in Africa in an Era of COVID- 19 and Planetary Biodiversity Loss. OMICS 2020 Dec 1;24(12):
682–4.
21. Rinschen, M. M., Ivanisevic, J., Giera, M., & Siuzdak, G. (2019). Identication of bioactive metabolites
using activity metabolomics. Nat. Rev. Mol. Cell Biol., 20(6), 353–367.
22. Salem, M. A., Perez de Souza, L., Serag, A., Fernie, A. R., Farag, M. A., Ezzat, S. M., & Alseekh, S..
Metabolomics in the context of plant natural products research: From sample preparation to metabolite
analysis. Metabolites 2020;10(1):37.
23. Pathak, R.K., Singh, D.B., Sagar, M., Baunthiyal, M., & Kumar, A. Computational approaches in drug
discovery and design. Comput Aided Drug Des. 2020 Jan 1;2020:1–21.
24. Gesto- Borroto, R., Medina- Jiménez, K., Lorence, A., & Villarreal, M.L. Application of DNA barcoding
for quality control of herbal drugs and their phytopharmaceuticals. Rev. Bras 2021 Apr 1;31(2):127–41.
25. Mishra, P., Kumar, A., Nagireddy, A., Mani, D.N., Shukla, A.K., Tiwari, R., et al. DNA barcoding: An
efcient tool to overcome authentication challenges in the herbal market. Plant Biotechnol. J. 2016 Jan
1;14(1):8–21.
26. Thakur, V.V., Tripathi, N., & Tiwari, S. DNA barcoding of some medicinally important plant species of
Lamiaceae family in India. Mol. Biol. Rep. 2021 Apr 1;48(4):3097–106.
27. Xin, T., Su, C., Lin, Y., Wang, S., Xu, Z., Phytomedicine, J.S. et al. Precise species detection of tradi-
tional Chinese patent medicine by shotgun metagenomic sequencing. Elsevier [Internet]. [cited 2024 Jul
18]; Available from: https://www.sciencedirect.com/science/article/pii/S094471131830148X
28. Sasidharan, S., Chen, Y., Saravanan, D., Sundram, K. M., & Latha, L. Y.. Extraction, isolation and char-
acterization of bioactive compounds from plants’ extracts. Afr. J. Tradit. Complement. Altern. Med.
2011;8(1). 10.4314/ajtcam.v8i1.60483
29. Karimi, A., Majlesi, M., & Raeian- Kopaei, M. Herbal versus synthetic drugs; beliefs and facts. J.
Nephropharmacol. 2015 [cited 2024 Jul 18]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC5297475/
30. Ekor, M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in
monitoring safety. Front. Neurol. 2014 4 Jan;4:177.
31. Ventola, C. L. Current issues regarding complementary and alternative medicine (CAM) in the United
States: part 1: the widespread use of CAM and the need for better- informed health care professionals to
provide patient counseling. Pharmacy and Therapeutics, 2010;35(8):461.
32. Anand, U., Tudu, C. K., Nandy, S., Sunita, K., Tripathi, V., Loake, G. J., … & Procków, J. (2022).
Ethnodermatological use of medicinal plants in India: From ayurvedic formulations to clinical perspectives–A review. J. Ethnopharmacol., 284, 114744.
33. Jaiswal, Y., Liang, Z., & Zhao, Z. Botanical drugs in Ayurveda and traditional Chinese medicine. J.
Ethnopharmacol. 2016. [cited 2024 Jul 18]; Available from: https://www.sciencedirect.com/science/
article/pii/S0378874116304123
34. Zhang, K., Zhang, Y., Li, N., Xing, F., Zhao, J., Yang, T., … & Feng, N.. An herbal- compound- based
combination therapy that relieves cirrhotic ascites by affecting the L- arginine/nitric oxide pathway: A
metabolomics- based systematic study. J. Ethnopharmacol. 2019;241:112034.
35. Chen, S.L., Yu, H., Luo, H.M., Wu, Q., Li, C.F., & Steinmetz, A. Conservation and sustainable use of
medicinal plants: Problems, progress, and prospects. Chin. Med. 2016 Jul 30;11(1):1–10.
36. Chokheli, V., Dmitriev, P., Rajput, V., & Plants, S.B. Recent development in micropropagation tech-
niques for rare plant species. Plants. 2020. [cited 2024 Jul 18]; Available from: https://www.mdpi.
com/2223-7747/9/12/1733
37. Hussain, M., Fareed, S., … Saeed, M. Current approaches toward production of secondary plant metabo-
lites. J. Pharm. Bioallied Sci.. 2012. [cited 2024 Jul 18]; Available from: https://journals.lww.com/jpbs/
fulltext/2012/04010/Current_approaches_toward_production_of_secondary.3.aspx
38. Chandran, H., Meena, M., Barupal, T., & Sharma, K.. Plant tissue culture as a perpetual source for pro-
duction of industrially important bioactive compounds. Biotechnol. Rep.. 2020;26:e00450.
39. Kayser, O. Ethnobotany and medicinal plant biotechnology: from tradition to modern aspects of drug
development. Planta Med. 2018 Aug 1;84(12–13):834–8.
Biotechnological Approaches for Herbal Drug Discovery 161
40. Singh, S., & Singh, V.K. Molecular dynamics simulation: methods and application. Frontiers in Protein
Structure, Function, and Dynamics 2020;213–38.
41. Patil, V.N., & Shahnawaz, M. Tissue culture approaches to enhance plant secondary metabolites produc-
tion. Biotechnological Approaches to Enhance Plant Secondary Metabolites: Recent Trends and Future
Prospects. 2021 Jan 1;89–97.
42. Corns, C.M. Herbal remedies and clinical biochemistry. Ann. Clin. Biochem. 2003 Sep;40(5):489–507.
43. Prasad, S., & Aggarwal, B. B. Turmeric, the golden spice. Biomolecular and Clinical Aspects. 2011. [cited
2024 Jul 18]; Available from: https://www.ncbi.nlm.nih.gov/books/n/herbalmed/ch13/?report=reader
44. Fasinu, P.S., Bouic, P.J., & Rosenkranz, B. An overview of the evidence and mechanisms of herb- drug
interactions. Front. Pharmacol. 2012;3 Apr:69.
45. Borse, S. P., Singh, D. P., & Nivsarkar, M. Understanding the relevance of herb–drug interaction studies
with special focus on interplays: a prerequisite for integrative medicine. Porto Biomed. J.. 2019. [cited
2024 Jul 18]; Available from: https://journals.lww.com/pbj/fulltext/2019/04000/Understanding_the_
relevance_of_herb_drug.1.aspx
46. Thomford, N. E., Dzobo, K., Chopera, D., Wonkam, A., Skelton, M., Blackhurst, D., … & Dandara, C..
Pharmacogenomics implications of using herbal medicinal plants on African populations in health transition. Pharmaceuticals 2015;8(3):637–663.
47. Liu, M.Z., Zhang, Y.L., Zeng, M.Z., He, F.Z., Luo, Z.Y., Luo, J.Q., et al. Pharmacogenomics and Herb-Drug
Interactions: Merge of Future and Tradition. Evidence-Based Complementary and Alternative Medicine.
2015 [cited 2024 Jul 18];2015. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1155/2015/
321091
48. Khan, S. L., Sonwane, G. M., Siddiqui, F. A., Jain, S. P., Kale, M. A., & Borkar, V. S. Discovery of
naturally occurring avonoids as human cytochrome P450 (CYP3A4) inhibitors with the aid of computational chemistry. Indo Glob J Pharm Sci. 2020. [cited 2024 Jul 19]; Available from: https://www.
academia.edu/download/78872062/09.-Khan- et- al.-2020.pdf
49. Zhang, Z., Ge, B., Zhou, L., Lam, T. N., & Zuo, Z. Induction of liver cytochrome P450s by Danshen–
Gegen formula is the leading cause for its pharmacokinetic interactions with warfarin. J. Ethnopharmacol..
2014. [cited 2024 Jul 18]; Available from: https://www.sciencedirect.com/science/article/pii/S0378874
114003353
50. Khashayar, A., Bahari, Z., Elliyeh, M., & Ghasemi, M. Therapeutic Effects of Berberine in Metabolic
Diseases and Diabetes Mellitus. Rev. Bras 2021 Jun 1;31(3):272–81.
51. Stanzione, F., Giangreco, I., & Cole, J. C. Use of molecular docking computational tools in drug dis-
covery. Prog. Med. Chem.. 2021. [cited 2024 Jul 18]; Available from: https://www.sciencedirect.com/
science/article/pii/S0079646821000047
52. Zhao, L., Ciallella, H. L., Aleksunes, L. M., & Zhu, H. Advancing computer- aided drug discovery
(CADD) by big data and data- driven machine learning modeling. Drug Discov. Today. 2020. [cited 2024
Jul 18]; Available from: https://www.sciencedirect.com/science/article/pii/S1359644620302646
53. Ramsay, R. R., Popovic- Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. A perspective on
multi- target drug discovery and design for complex diseases. Clin. Transl. Med.. 2018 Dec [cited 2024
Jul 18];7(1):3. Available from: https://link.springer.com/article/10.1186/s40169-017-0181-2
54. Rifaioglu, A. S., Atas, H., Martin, M. J., Cetin- Atalay, R., Atalay, V., & Dogan, T. Recent applications of
deep learning and machine intelligence on in silico drug discovery: methods, tools and databases. Brief.
Bioinform.. 2019. [cited 2024 Jul 19]; Available from: https://academic.oup.com/bib/article- abstract/
20/5/1878/5062947
55. Schenone, M., Dancík, V., Wagner, B. K., & Clemons, P. A. Target identication and mechanism of
action in chemical biology and drug discovery. Nat. Chem. Biol.. 2013. [cited 2024 Jul 18]; Available
from: https://www.nature.com/articles/nchembio.1199
56. Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R.K., & Kumar, P. Articial intelligence to deep
learning: machine intelligence approach for drug discovery. Mol. Divers. 2021 Aug 1;25(3):1315–60.
57. Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E.W. Computational methods in drug discovery. Pharmacol.
Rev.. 2014. [cited 2024 Jul 18]; Available from: https://pharmrev.aspetjournals.org/content/66/1/334.short
58. Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chen, L., Crichlow, G. V., … & Zhuravleva, M. RCSB
Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for
basic and applied research and education in fundamental. Nucleic Acids Res.. 2021. [cited 2024 Jul 18];
Available from: https://academic.oup.com/nar/article- abstract/49/D1/D437/5992282
162 Herbal Pharmacopeia
59. Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. Natural
products for drug discovery in the 21st century: innovations for novel drug discovery. Int. J. Mol. Sci..
2018. [cited 2024 Jul 18]; Available from: https://www.mdpi.com/1422-0067/19/6/1578
60. Batool, M., Ahmad, B., & Choi, S. A structure- based drug discovery paradigm. Int. J. Mol. Sci.. 2019.
[cited 2024 Jul 18]; Available from: https://www.mdpi.com/1422-0067/20/11/2783
61. Gertsch, J. undened. Botanical drugs, synergy, and network pharmacology: forth and back to intelligent
mixtures. Planta Med.. 2011 [cited 2024 Jul 18];77(11):1086–98. Available from: https://www.thieme-
connect.com/products/ejournals/html/10.1055/s- 0030-1270904
62. Singh, D. B., & Pathak, R. K. Computational approaches in drug designing and their applications.
Exp. Protoco. Biotechnol.. 2020 [cited 2024 Jul 18];95–117. Available from: https://link.springer.com/
protocol/10.1007/978-1-0716-0607-0_6
63. Selg, E., Buccellati, C., Andersson, M., Rovati, G.E., Ezinga, M., Sala, A., et al. Antagonism of thrombox-
ane receptors by diclofenac and lumiracoxib. Br. J. Pharmacol. 2007 [cited 2024 Jul 18];152(8):1185–
95. Available from: https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1038/sj.bjp.0707518
64. Pathak, R. K., Gupta, A., Shukla, R., & Baunthiyal, M. Identication of new drug- like compounds
from millets as Xanthine oxidoreductase inhibitors for treatment of Hyperuricemia: A molecular docking and simulation study. Comput. Biol. Chem. 2018 [cited 2024 Jul 18]; Available from: https://www.
sciencedirect.com/science/article/pii/S1476927118300173
65. Agnihotry, S., Pathak, R.K., Srivastav, A., Shukla, P.K., & Gautam, B. Molecular docking and structure-
based drug design. Comput Aided Drug Des. 2020 Jan 1;115–31.
66. Pathak, R.K., Singh, D.B., Sagar, M., Baunthiyal, M., & Kumar, A. Computational approaches in drug
discovery and design. Comput Aided Drug Des. 2020 Jan 1;1–21.
67. Sharma, A., Kumar, L., Malhotra, M., Singh, A.P., & Singh, A.P. Ananas comosus (Pineapple): A com-
prehensive review of its medicinal properties, phytochemical composition, and pharmacological activities. J. Drug Deliv. Ther. 2024 May 15;14(5):148–57.
68. Asase, A. Ghana’s herbal medicine industry: prospects, challenges and ways forward from a developing
country perspective. Front. Pharmacol. 2023;14:1267398.
69. Wang, H., Chen, Y., Wang, L., Liu, Q., Yang, S., & Wang, C. Advancing herbal medicine: enhancing
product quality and safety through robust quality control practices. Front. Pharmacol. 2023;14:1265178.
70. Wang, Y., Yang, S.H., Zhong, K., Jiang, T., Zhang, M., Kwan, H.Y., et al. Network Pharmacology- Based
Strategy for the Investigation of the Anti- Obesity Effects of an Ethanolic Extract of Zanthoxylum bungeanum Maxim. Front. Pharmacol. 2020 Nov 13;11:572387.
71. Guan, Y., Tang, G., Li, L., Shu, J., Zhao, Y., Huang, L., & Tang, J. Herbal medicine and gut microbiota:
exploring untapped therapeutic potential in neurodegenerative disease management. Arch. Pharm. Res..
2024 Feb 1 [cited 2024 Jul 19];47(2):146–64. Available from: https://link.springer.com/article/10.1007/
s12272-023-01484-9
72. Tian, S., Li, Y., Xu, J., Zhang, L., Zhang, J., Lu, J., et al. COIMMR: a computational framework to reveal
the contribution of herbal ingredients against human cancer via immune microenvironment and metabolic reprogramming. Brief. Bioinform. 2023 Nov 1;24(6):bbad346.
73. Hou, Y. N., Chimonas, S., Gubili, J., Deng, G., & Mao, J. J. Integrating herbal medicine into oncol-
ogy care delivery: development, implementation, and evaluation of a novel program. Support. Care
Cancer. 2023 Feb 1 [cited 2024 Jul 18];1(2):3. Available from: https://link.springer.com/article/10.1007/
s00520-023-07577-x
74. Shahare, N., Chouhan, S., & Darwhekar, G.N. Herbs used in treatment of mouth ulcer- a review. Int. J.
Pharmacogn. Chem. 2021 Jul 29;68–74. https://doi.org/10.46796/ijpc.v2i3.212
75. Jun, J.H., Ang, L., Choi, T.Y., Lee, H.W., & Lee, M.S. Integrative medicine (Herbal medicine combined
with drug therapy) for behcet’s disease: A systematic review and meta- analysis of randomized controlled
trials. Pharmaceutics. 2021;13(4):476.
76. Theuser, A.K., Hack, C.C., Fasching, P.A., Antoniadis, S., Grasruck, K., Wasner, S., et al. Patterns and
Trends of Herbal Medicine Use among Patients with Gynecologic Cancer. Geburtshilfe Frauenheilkd.
2021 Jun 1;81(6):699–707.
77. David, L., Thakkar, A., Mercado, R., & Engkvist, O. Cheminformatics OEJ of, 2020 undened. Molecular
representations in AI- driven drug discovery: a review and practical guide. J.Cheminform., 2020 Sep 17
[cited 2024 Jul 18];12(1). Available from: https://link.springer.com/article/10.1186/s13321-020-00460-5
78. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R.K. Articial intelligence in drug
discovery and development. Drug Discov. Today 2021 Jan 1;26(1):80–93.
Biotechnological Approaches for Herbal Drug Discovery 163
79. Park, M.N. The Therapeutic Potential of a Strategy to Prevent Acute Myeloid Leukemia Stem Cell
Reprogramming in Older Patients. Int. J. Mol. Sci. 2023 Aug 1;24(15):12037.
80. Cox, P.B., & Gupta, R. Contemporary computational applications and tools in drug discovery. ACS Med.
Chem. Lett. 2022 Jul 14;13(7):1016–29.
81. Li, C., Jia, W. W., Yang, J. L., Cheng, C., & Olaleye, O. E. Multi- compound and drug- combination phar-
macokinetic research on Chinese herbal medicines. Acta Pharmacol. Sin.. 2022 Dec 1 [cited 2024 Jul
18];43(12):3080–95. Available from: https://www.nature.com/articles/s41401-022-00983-7
82. Gaudêncio, S.P., Bayram, E., Lukic Bilela, L., Cueto, M., Díaz- Marrero, A.R., Haznedaroglu, B.Z., et
al. Advanced methods for natural products discovery: bioactivity screening, dereplication, metabolomics
proling, genomic sequencing, databases and informatic tools, and structure elucidation. Mar. Drugs
2023 May 1;21(5):308.
83. Wishart, D.S. Applications of metabolomics in drug discovery and development. Drugs R&D 2008;9(5):
307–22.
84. Kosmides, A. K., Kamisoglu, K., Calvano, S. E., Corbett, S. A., & Androulakis, I. Metabolomic n-
gerprinting: challenges and opportunities. Crit. Rev. Biomed. Eng.. 2013 [cited 2024 Jul 18]; Available
from: https://www.dl.begellhouse.com/journals/4b27cbfc562e21b8,4863d6072e2ac4d2,7fd840d0527bd
32e.html
85. Chiu, H. H., & Kuo, C. H. Gas chromatography- mass spectrometry- based analytical strategies for fatty
acid analysis in biological samples. J. Food Drug Anal. 2020. [cited 2024 Jul 18]; Available from: https://
www.sciencedirect.com/science/article/pii/S1021949819300985
86. Chiu, H. H., & Kuo, C. H. Mass spectrometry-based forest tree metabolomics. Mass Spectrom. Rev.. 2019
Mar 1 [cited 2024 Jul 18];40(2):126–57. Available from: https://analyticalsciencejournals.onlinelibrary.
wiley.com/doi/abs/10.1002/mas.21603?casa_token=j2ZND51fsdEAAAAA:vGpAqg6Dl70a_cQrGyyT
VvW8I1rwcQ3XkWMy7Q0LCPtzI55YFIlBkMB1YgO1i0-n00jAVDPF- 1Pppp_nkQ
87. Wang, R., Yin, Y., & Zhu, Z.J. Advancing untargeted metabolomics using data- independent acquisition
mass spectrometry technology. Anal. Bioanal. Chem. 2019 Jul 19]411(19):4349–57.
88. Wang, S., Blair, I.A., & Mesaros, C. Analytical methods for mass spectrometry- based metabolomics
studies. Adv. Exp. Med. Biol. 2019;1140:635–47.
89. Duncan, K. D., Fyrestam, J., & Lanekoff, I. Advances in mass spectrometry based single- cell metab-
olomics. Analyst. 2019 [cited 2024 Jul 18];144:782. Available from: https://pubs.rsc.org/en/content/
articlehtml/2019/an/c8an01581c
90. Diez- Simon, C., Mumm, R., & Hall, R. D. Mass spectrometry- based metabolomics of volatiles as a new
tool for understanding aroma and avour chemistry in processed food products. Metabolomics. 2019.
123AD Mar 1 [cited 2024 Jul 18];1(3):41. Available from: https://link.springer.com/article/10.1007/
s11306-019-1493-6
91. Vignoli, A., Ghini, V., Meoni, G., Licari, C., Takis, P.G., Tenori, L., et al. High- throughput metabolomics
by 1D NMR. Angew. Chem. Int. Ed. 2019 Jan 21;58(4):968–94.
92. Ranjan, R, & Sinha, N. Nuclear magnetic resonance (NMR)-based metabolomics for cancer research.
NMR Biomed.. 2018 Oct 1 [cited 2024 Jul 18];32(10). Available from: https://analyticalsciencejournals.
onlinelibrary.wiley.com/doi/abs/10.1002/nbm.3916?casa_token=UnmadNHf_WEAAAAA:52708
Uji6g_LVZ- uHX_UxgD4sp05axyVBaWVe0AslHOePOUhJdj6hy1s0Gj_28x_kl- 6WQi_xjb3Ghe78w
93. Lucas- Torres, C., & Wong, A. Current developments in μMAS NMR analysis for metabolomics.
Metabolites. 2019 [cited 2024 Jul 18]; Available from: https://www.mdpi.com/2218-1989/9/2/29
94. Consonni, R., & Cagliani, L.R. The potentiality of NMR-based metabolomics in food science and food authen-
tication assessment. Magn. Reson. Chem. 2019. 2018 Sep 1 [cited 2024 Jul 18];57(9):558–78. Available
from: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/mrc.4807?casa_token=
F6zAVMHagCAAAAAA:8V- RpHPM77ucKTwmL_3jytoMnsG4KdJq0Z- 5LN1POf0MDh- Var3
eeyZ2NoIfVWPW_SLHNxHSQXprcn1S_w
95. Song, Z., Wang, H., Yin, X., Deng, P., & Jiang, W. Application of NMR metabolomics to search for
human disease biomarkers in blood. Clin. Chem. Lab. Med. 2019 Apr 1;57(4):417–41.
96. De Castro, F., Benedetti, M., Del Coco, L., & Fanizzi, F. P. NMR- based metabolomics in metal- based
drug research. Molecules. 2019. [cited 2024 Jul 19]; Available from: https://www.mdpi.com/1420-3049/
24/12/2240
97. Volpe, M.G., Costantini, S., Coccia, E., Parrillo, L., & Paolucci, M. Evaluation of metabolic changes
induced by polyphenols in the craysh Astacus leptodactylus by metabolomics using Fourier transformed infrared spectroscopy. J. Biosci. 2018 Sep 1;43(4):585–96.